EB
EBS.US Emergent Biosolutions Inc
- Market cap
- USD 298M
- P/E
- -
- P/B
- 0.97x
- ROE
- -87.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is EBS.US undervalued?
Graham numberThe Graham number of Emergent Biosolutions Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Emergent Biosolutions Inc fundamental analysis
No fundamental analysis for Emergent Biosolutions Inc yet.
Emergent Biosolutions Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Emergent Biosolutions Inc
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhala…
Full company profileEmergent Biosolutions Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Emergent Biosolutions Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 489M | 561M | 782M | 1.11B | 1.58B | 1.77B | 1.12B | 1.05B | 1.04B | 743M | 667M |
| Gross Profit | 245M | 284M | 320M | 483M | 863M | 793M | 473M | 360M | 375M | 351M | 298M |
| Operating Income | 106M | 124M | 89.8M | 114M | 439M | 341M | -170M | -726M | -109M | 110M | -203M |
| EBITDA | 133M | 175M | 155M | 262M | 614M | 510M | 34.0M | -43.0M | 56.6M | 238M | -140M |
| Net Income | 51.8M | 82.6M | 62.7M | 54.5M | 306M | 220M | -212M | -761M | -191M | 52.6M | -275M |
| EPS | 1.05 | 1.64 | 1.22 | 1.04 | 5.68 | 4.06 | -4.22 | -15 | -3.60 | 0.93 | -5.36 |
| Balance Sheet | |||||||||||
| Total Assets | 970M | 1.07B | 2.23B | 2.33B | 2.88B | 2.96B | 3.17B | 1.82B | 1.39B | 1.32B | 995M |
| Total Liabilities | 374M | 158M | 1.22B | 1.24B | 1.44B | 1.35B | 1.78B | 1.17B | 907M | 796M | 682M |
| Shareholders' Equity | 596M | 912M | 1.01B | 1.09B | 1.45B | 1.61B | 1.39B | 649M | 483M | 523M | 313M |
| Cash & Short-term Investments | 272M | 178M | 112M | 168M | 621M | 576M | 643M | 112M | 99.5M | 205M | 176M |
| Total Debt | 268M | 56.2M | 795M | 837M | 923M | 871M | 1.43B | 860M | 676M | 572M | 508M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 53.5M | 208M | 41.8M | 188M | 537M | 321M | -34.1M | -206M | 58.7M | 171M | 163M |
| Capital Expenditure | 76.3M | 54.8M | 72.1M | 86.9M | 142M | 225M | 116M | 51.6M | 22.9M | 13.8M | 10.4M |
| Free Cash Flow | -22.8M | 153M | -30.3M | 101M | 395M | 96.1M | -150M | -258M | 35.8M | 157M | 153M |
| Ratios | |||||||||||
| ROE | 8.7% | 9.1% | 6.2% | 5.0% | 21.1% | 13.6% | -15.2% | -117.1% | -39.5% | 10.1% | -87.7% |
| ROA | 5.3% | 7.7% | 2.8% | 2.3% | 10.6% | 7.4% | -6.7% | -41.7% | -13.7% | 4.0% | -27.6% |
| Net Profit Margin | 10.6% | 14.7% | 8.0% | 4.9% | 19.4% | 12.4% | -18.9% | -72.5% | -18.3% | 7.1% | -41.2% |
| Debt to Equity | 0.45x | 0.06x | 0.79x | 0.77x | 0.64x | 0.54x | 1.03x | 1.32x | 1.40x | 1.09x | 1.62x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Emergent Biosolutions Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 5.00M | 0.10 | - |
| 2022 | - | - | - |
| 2021 | USD 15.9M | 0.29 | 7.2% |
| 2020 | USD 17.8M | 0.33 | 5.8% |
| 2019 | USD 800K | 0.02 | 1.5% |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Emergent Biosolutions Inc
- Insiders 4.20%
- Institutions 91.43%
- Public & others 4.37%
- Shares outstanding 51.4M
- Free float 49.2M
Top funds holding EBS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Avantis US Small Cap Value ETF | 3.05M | 5.93% | +0.36% | Oct 2026 |
| State Street® SPDR® S&P® Biotech ETF | 1.73M | 3.37% | +2.69% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.55M | 3.02% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.35M | 2.63% | 0.00% | Oct 2026 |
| DFA U.S. Small Cap Value I | 823K | 1.60% | +16.65% | Sep 2026 |
| Fidelity Small Cap Index | 569K | 1.11% | 0.00% | Aug 2026 |
| iShares U.S. Small-Cap Eq Fac ETF | 557K | 1.08% | 0.00% | Oct 2026 |
| Fidelity Enhanced Small Cap Core ETF | 551K | 1.07% | +0.27% | Oct 2026 |
| Vanguard Strategic Equity Inv | 529K | 1.03% | 0.00% | Sep 2026 |
| iShares Russell 2000 Value ETF | 503K | 0.98% | 0.00% | Oct 2026 |
| Schwab Fundamental U.S. Small CompanyETF | 408K | 0.79% | 0.00% | Oct 2026 |
| iShares Biotechnology ETF | 379K | 0.74% | -0.19% | Oct 2026 |
| PIMCO RAE US S Instl | 351K | 0.68% | +6.15% | Jun 2026 |
| Federated Hermes MDT Small Cap Core IS | 318K | 0.62% | -49.56% | Sep 2026 |
| Dimensional US Small Cap Value ETF | 306K | 0.60% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 303K | 0.59% | +1.50% | Sep 2026 |
| DFA U.S. Targeted Value I | 278K | 0.54% | -37.34% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 268K | 0.52% | +0.24% | Oct 2026 |
| DFA U.S. Small Cap I | 227K | 0.44% | 0.00% | Sep 2026 |
| Dimensional US Targeted Value ETF | 220K | 0.43% | 0.00% | Oct 2026 |
Top institutions holding EBS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 4.72M | 9.17% | +8.64% | Jun 2026 |
| State Street Corp | 2.93M | 5.70% | +2.79% | Jun 2026 |
| American Century Companies Inc | 2.77M | 5.39% | +14.21% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 2.57M | 4.99% | -16.56% | Sep 2026 |
| Vanguard Capital Management, LLC | 2.20M | 4.28% | -2.62% | Jun 2026 |
| LSV Asset Management | 1.70M | 3.30% | +89.12% | Jun 2026 |
| Acadian Asset Management LLC | 1.34M | 2.61% | -2.70% | Jun 2026 |
| Geode Capital Management, LLC | 1.34M | 2.60% | +5.05% | Jun 2026 |
| Charles Schwab Investment Management Inc | 1.20M | 2.34% | -20.27% | Jun 2026 |
| Oak Hill Advisors LP | 1.11M | 2.17% | 0.00% | Jun 2026 |
| Millennium Management LLC | 1.07M | 2.09% | +101.54% | Jun 2026 |
| Ancora Advisors LLC | 1.07M | 2.08% | +160.92% | Jun 2026 |
| AQR Capital Management LLC | 1.04M | 2.03% | +5.20% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.04M | 2.01% | +27.58% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.03M | 2.00% | -7.87% | Jun 2026 |
| D. E. Shaw & Co LP | 900K | 1.75% | -10.34% | Jun 2026 |
| Federated Hermes Inc | 831K | 1.62% | +82.14% | Jun 2026 |
| Prudential Financial Inc | 806K | 1.57% | +79.56% | Jun 2026 |
| Prescott Group Capital Management LLC | 773K | 1.50% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 683K | 1.33% | +4.15% | Jun 2026 |
Emergent Biosolutions Inc company profile
- Company name
- Emergent Biosolutions Inc
- Ticker
- EBS.US
- Exchange
- USA Stocks
- Listed since
- Nov 15, 2006
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 900
- Fiscal year end
- December
- Address
- 300 Professional Drive, Gaithersburg, MD, United States, 20879
- Phone
- 240 631 3200
- Website
- emergentbiosolutions.com
About Emergent Biosolutions Inc
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose. In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Emergent Biosolutions Inc management
10- Mr. Joseph C. Papa Jr., M.B.A., R.Ph.CEO, President & Director · born 1956
- Mr. Richard S. Lindahl M.B.A.Executive VP, CFO and Principal Financial & Accounting Officer · born 1964
- Ms. Coleen GlessnerExecutive Vice President of Quality, Ethics & Compliance · born 1971
- Mr. Paul A. WilliamsSenior Vice President of Products Business · born 1967
- Ms. Jessica PerlSenior VP, Corporate Secretary & General Counsel · born 1981
- Assal HellmerVice President of Communications
- Ms. Michelle PepinSenior VP & Chief Human Resource Officer
- Ms. Stephanie DuatschekExecutive VP & Chief Growth Officer
- Mr. William HartzelSenior Vice President of Manufacturing & Bioservices · born 1978
- Mr. Frank VargoVP & Treasurer · born 1983